FDA clears Interpore's bone void filler:
This article was originally published in Clinica
Executive Summary
The US FDA has cleared Interpore Cross International's bone void filler, BonePlast. The biocompatible, calcium sulphate-based material that resorbs and is replaced with bone during the healing process may be used in bony voids of the skeletal system, such as the extremities, spine and pelvis. It has a mouldable, dough-like consistency and remains workable for around six to eight minutes before hardening. The Irvine, California-based company plans to begin selling the product later this year.
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.